One Model, Three Jobs: How Foundation Models Are Collapsing the Drug Discovery Pipeline

Picture a pharmaceutical research operation from five years ago: one team hunting for druggable protein targets, a second generating candidate molecules, a third running toxicity screens, and a project manager whose entire job description was making sure those three groups talked to each other at least once a week. Now picture a small computational biology group in 2025, running all three of those workflows through a single foundation model pipeline before lunch. That compression is not a pitch deck fantasy. It is what the peer-reviewed review "From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes," published on NIH's PubMed Central (PMC12298131), positions as the current trajectory of AI-assisted early-stage drug discovery. For anyone building a career at the intersection of machine learning and biomedicine, this is worth sitting with carefully , not because AI is doing all the science now (it is not), but because the organizational logic of early drug discovery is being rewritten, and the skill sets that travel best are shifting with it.

What Foundation Models Actually Do in

a Drug Discovery Pipeline The phrase "foundation model" gets used promiscuously enough that it is worth being precise. Foundation models are large-scale, pre-trained neural networks that learn generalizable representations from diverse data sources. In drug discovery specifically, as Arctoris details in their analysis of the field, these models are trained on small molecule structures, protein sequences, biological assay data, and omics profiles. Once trained, they can be fine-tuned for a range of downstream tasks: target identification, virtual screening, de novo molecular design, and lead optimization. The key word is fine-tuned , you are not training a new model from scratch for each task; you are adapting a shared representational backbone. If that sounds familiar, it should: it is the same conceptual move that made large language models useful across wildly different text tasks (summarization, translation, code generation), except now the vocabulary is atoms and binding affinities rather than words and syntax. What makes this architecture particularly interesting for drug discovery is the nature of the tasks being unified. Target identification asks: which biological molecule, if blocked or activated, would address this disease? Molecular generation asks: what chemical structure would interact with that target effectively? Toxicity prediction asks: will this compound damage the patient before it helps them? Historically, these questions required different data modalities, different domain expertise, and often entirely different software stacks maintained by entirely different people. A foundation model trained broadly enough can develop representations that are relevant to all three, which is a genuinely different way of organizing the early research phase , less like a relay race, more like one very well-read generalist running all three legs simultaneously.

The Workflow Compression Story, Grounded in Evidence

The PMC review (PMC12298131) is the anchor source here, and it is worth naming why: it is peer-reviewed, NIH-hosted, and specifically covers the applied ML dimension of drug discovery timelines and industry outcomes. It situates AI not as a speculative add-on but as an active structural force in how early-stage research is organized. The review's framing aligns with what Frontiers in Bioinformatics published under the title "Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications," which similarly covers AI across the full arc from molecular representation to pipeline-level deployment. Both publications point in the same direction: the interesting story is not that any single AI tool is faster at any single task; it is that a sufficiently capable model can serve as the connective tissue between tasks that used to be siloed. NVIDIA's BioNeMo platform is one concrete illustration of this direction in practice. According to NVIDIA's own documentation of the platform, the latest BioNeMo foundation models can analyze DNA sequences, predict how proteins will change shape in response to a drug molecule, and determine a cell's function based on its RNA , capabilities that span what would traditionally be considered separate experimental and computational disciplines. NVIDIA has also announced that BioNeMo models are available as microservices through NVIDIA NIM, and that the models will soon be accessible on AWS HealthOmics, described by NVIDIA as a purpose-built service that helps healthcare and life sciences organizations store, query, and analyze biological data. The infrastructure story and the model story are converging: accessible APIs over powerful biological foundation models lower the barrier for smaller teams to operate at a scope that previously required large institutional resources.

Where the Limits Live (and

Why They Matter for Learners) None of this means the pipeline has been fully automated or that domain expertise is optional. Foundation models in drug discovery inherit real constraints from their training data. The Stanford CRFM report "On the Opportunities and Risks of Foundation Models" (Bommasani et al.), which remains a foundational reference on the broader category, discusses how models surface limitations tied to the data they were trained on , and in drug discovery contexts, that includes the historical distribution of what compounds and targets have actually been studied. A model that has seen ten thousand variants of one class of protein and fifty examples of another will not treat them equally, regardless of what the disease biology requires. Understanding where a model's confidence is calibrated versus where it is extrapolating is a genuinely important skill for anyone deploying these tools in a research setting , and it is not a skill the model teaches you automatically. The Frontiers in Bioinformatics paper on AI in drug discovery from advanced molecular representation to pipeline applications addresses this directly in its scope: getting from molecular representation to pipeline deployment involves deliberate choices about data curation, model selection, and evaluation criteria that a practitioner has to make actively. The compression of multi-team workflows into a unified pipeline does not eliminate the need for scientific judgment; it relocates where that judgment needs to be applied. Instead of three specialized teams negotiating handoffs, you have one smaller team that needs to understand enough of all three domains to catch errors that previously would have been caught at the handoff point. That is a different skill profile, not a simpler one.

What This Means

If You Are Building Toward a Biotech ML Career The practical implication for learners is that the 2025-2026 hiring landscape in computational biology and cheminformatics is increasingly shaped by people who can work at the seams. Pure cheminformatics specialists who cannot reason about model architectures, and pure ML engineers who cannot read an assay readout, are both less useful than they were when the workflows were separate enough to stay in separate lanes. The PMC review (PMC12298131) and the supporting literature collectively suggest that the most valuable people in this space right now are the ones who understand enough chemistry to sanity-check a molecular generation output, enough biology to evaluate a target identification result, and enough ML to debug a fine-tuning pipeline when it drifts. That is a lot to ask, which is also why the gap is real and the opportunity is real. If you are a learner mapping out a curriculum for this space, the Frontiers in Bioinformatics paper on molecular representation and pipeline applications is a useful technical map of where the methods currently stand. The PMC review is the institutional-level view of where the industry is heading. NVIDIA BioNeMo is a live platform worth exploring for hands-on familiarity with what foundation model microservices for biology actually look like in practice. And the Stanford CRFM report on foundation models remains a worthwhile read for understanding the broader conceptual framework these drug discovery tools are an instance of. The field is moving fast enough that reading six months of literature puts you ahead of a surprisingly large fraction of people who have job titles in the space. That gap closes, but it has not closed yet.